Significance of Pathologic Response in Patients With Early and Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy in a Middle-Income Country. A Real-World Historical Cohort

dc.contributor.authorMantilla, William
dc.contributor.authorGonzalez Blanco, Mariafernanda
dc.contributor.authorRojas, Sebastian
dc.contributor.authorGuerra, Joaquin Hernando
dc.contributor.authorMunevar, Isabel
dc.date.accessioned2025-01-31T19:39:57Z
dc.date.available2025-01-31T19:39:57Z
dc.date.issued2024-07-11
dc.description.abstractPURPOSE Breast cancer (BC) is the most frequent neoplasm in women in Colombia and is associated with a higher mortality rate than in other countries and regions. Neoadjuvant chemotherapy (NACT) has become a standard treatment in locally advanced BC and provides an opportunity to improve clinical outcomes in BC. This study aims to describe characteristics, treatment patterns, and outcomes after NACT in a cohort of Colombian patients with BC. METHODS We performed a retrospective cohort study. We included adult patients with BC treated with NACT. Clinical charts were retrospectively reviewed. Descriptive statistics and time to event for overall survival analyses were performed. Recursive partitioning was performed for survival curves to assess the complex relationship between survival times and other variables. RESULTS Three hundred and fourteen patients were included for analysis. The pathologic complete response after neoadjuvant chemotherapy (ypCR) rate was 34.4%, with a higher ypCR in triple-negative BC (TNBC; 46.9%) and human epidermal growth factor receptor 2–positive BC (72.7%). Thosewho did not achieve ypCR had a higher percentage of death and relapse.Themedian follow-up was 4.9 years, with an 88.2% 5-year overall survival (OS). CONCLUSION A total of 62.6% of the total patients identified were not treated with NACT, indicating a low utilization. Our global ypCR rate was higher when compared with similar studies in Colombia, likely because of differences in the NACT treatment regimens. ypCR was only associated with OS in the TNBC subgroup, emphasizing the importance of pursuing ypCR in these patients. We consider the use of NACT a valuable opportunity to implement innovative treatment approaches that improve outcomes in Colombian patients with BC.
dc.identifier.citationMantilla, W., Gonzalez, M., Rojas, S., Borras-Osorio, M., Molano-Gonzalez, N., Moran, D., Guerra, J. H., Romero, O., Munevar, I., & ICAROS Research Group. (2024). Significance of pathologic response in patients with early and locally advanced breast cancer treated with neoadjuvant chemotherapy in a middle-income country. A real-world historical cohort. JCO Global Oncology, 10(10), e2300187. https://doi.org/10.1200/GO.23.00187
dc.identifier.urihttps://hdl.handle.net/20.500.14595/836
dc.language.isoen_US
dc.publisherJCO Global Oncology
dc.titleSignificance of Pathologic Response in Patients With Early and Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy in a Middle-Income Country. A Real-World Historical Cohort
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
mantilla-et-al-2024-significance-of-pathologic-response-in-patients-with-early-and-locally-advanced-breast-cancer.pdf
Size:
685.79 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:

Collections